Mola Hidatidosa

01Pathophysiology

Hydatidiform mole is a form of gestational trophoblastic disease (GTD) arising from abnormal fertilization. The core defect is an imbalance in parental genetic contribution, which causes unchecked trophoblastic proliferation and hydropic degeneration of chorionic villi.

In a complete mole, an empty ovum (one that has lost its maternal nuclear DNA) is fertilized by one sperm that duplicates its chromosomes (46,XX) or, less commonly, by two sperm (46,XY). The entire genome is paternal. Because trophoblast differentiation is driven by the paternal genome while embryonic tissue differentiation relies on the maternal genome, you get massive trophoblastic growth with no fetal tissue. The villi become universally swollen and edematous, forming the characteristic grape-like vesicles. The all-paternal genome drives aggressive trophoblastic proliferation, which explains the markedly elevated beta-hCG and the higher risk of progression to gestational trophoblastic neoplasia (GTN), approximately 15 to 20%.

In a partial mole, a normal ovum retains its maternal DNA but is fertilized by two sperm, producing a triploid karyotype (69,XXX or 69,XXY). Because maternal genetic material is present, some fetal tissue or fetal parts may develop, though the fetus is never viable. The trophoblastic proliferation is focal rather than diffuse, hCG levels are less dramatically elevated, and the risk of malignant transformation is lower (around 1 to 5%).

The markedly elevated hCG in complete moles has direct clinical consequences. Theca lutein cysts form bilaterally in the ovaries because excessive hCG overstimulates the granulosa and theca cells. The hCG can also cross-react with the TSH receptor due to structural similarity of their alpha subunits, causing secondary hyperthyroidism with tachycardia, tremor, and heat intolerance. Severe nausea (hyperemesis) is driven by the very high hCG levels as well.

The reason a patient presents with first-trimester bleeding is that the hydropic villi outgrow their blood supply and disrupt the decidual-trophoblast interface, leading to hemorrhage into the uterine cavity.

02Classification and Clinical Manifestation

A key exam point: complete moles present dramatically (large uterus, very high hCG, snowstorm on ultrasound), while partial moles present subtly and are frequently diagnosed only after pathologic examination of products of conception from a presumed miscarriage.

03Diagnostic Workup

Quantitative beta-hCG is the first test you order when a molar pregnancy is suspected. A level that is far higher than expected for the stated gestational age, particularly in a patient with first-trimester bleeding and an enlarged uterus, should immediately raise suspicion. In a complete mole, values above 100,000 mIU/mL are typical.

Pelvic ultrasound is the best initial imaging study. In a complete mole, you see a heterogeneous echogenic mass filling the uterine cavity with multiple small cystic spaces ("snowstorm" appearance) and no identifiable fetal pole or cardiac activity. In a partial mole, the ultrasound may show a gestational sac with abnormal placental tissue and, in some cases, identifiable but abnormal fetal structures. Bilateral theca lutein cysts may be visible on the ovaries if hCG is very high.

The gold standard for diagnosis is histopathologic examination of the evacuated tissue. The pathologist looks for hydropic swelling of chorionic villi and the degree of trophoblastic proliferation. A critical immunohistochemical marker is p57, a maternally imprinted, paternally silenced gene product. In a complete mole, because no maternal genome is present, p57 staining is negative in villous cytotrophoblast and stromal cells. In a partial mole, p57 is positive because maternal DNA is present. This distinction is high-yield when a vignette asks how to differentiate complete from partial mole on pathology.

A baseline chest X-ray is obtained before or shortly after evacuation to screen for pulmonary metastases, which is relevant for staging if GTN develops.

04Management and Treatment

Suction curettage is the treatment of choice for uterine evacuation, regardless of uterine size. Hysterotomy and induction with prostaglandins or oxytocin are avoided as primary methods because they increase the risk of trophoblastic dissemination and hemorrhage. IV oxytocin is infused once cervical dilation begins to promote uterine contraction and minimize blood loss. Sharp curettage may follow suction to ensure the cavity is completely evacuated.

For patients who have completed childbearing, hysterectomy is an alternative. The uterus is removed with the mole in situ. However, even after hysterectomy, hCG monitoring is still required because trophoblastic tissue may have already spread hematogenously.

Serial beta-hCG monitoring is the cornerstone of post-evacuation management. After evacuation, hCG should fall progressively. The levels are checked weekly. Once hCG reaches undetectable levels for three consecutive weekly measurements, monitoring switches to monthly. For a complete mole, monthly surveillance continues for 6 additional months after the first undetectable value. For a partial mole, the monitoring period is typically 6 months total from evacuation. During this entire surveillance window, the patient must use reliable contraception (oral contraceptive pills are acceptable and do not increase GTN risk) because a new pregnancy would produce hCG and confound the monitoring.

If beta-hCG plateaus (remains unchanged across four measurements over three weeks) or rises (increases across three consecutive weekly measurements), the diagnosis shifts to gestational trophoblastic neoplasia. The patient then undergoes staging workup (pelvic ultrasound, CT chest/abdomen/pelvis, brain MRI if indicated) and receives chemotherapy. Single-agent methotrexate is first-line for low-risk GTN. Multi-agent regimens (EMA-CO: etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) are used for high-risk disease.

05Differential Diagnosis and Distractors

The most tested distractor pair is complete mole vs. partial mole within the same question. Vignettes will present features that overlap and ask you to distinguish them. The discriminators: complete mole has no fetal tissue, diffusely hydropic villi, very high hCG, and uterus larger than dates. Partial mole may show fetal parts, triploid karyotype, and less dramatic hCG elevation.

Another common distractor is choriocarcinoma vs. complete mole. Both produce very high hCG and vaginal bleeding. The key: choriocarcinoma is a malignancy that invades myometrium and metastasizes hematogenously (lung most common), and histology shows no chorionic villi (pure malignant trophoblastic tissue). A mole retains villous architecture on pathology.

06Traps and High-Yield Pearls

The most common way students get questions on hydatidiform mole wrong is by failing to distinguish complete from partial mole based on the clinical and pathologic clues in the vignette. Test-writers love to present a partial mole that was initially misdiagnosed as a spontaneous abortion. The trap: the student sees "vaginal bleeding" and "passage of tissue" and jumps to missed abortion without recognizing the clue of a mildly elevated hCG or triploid karyotype on genetic analysis. The teaching point is that all products of conception from first-trimester losses should undergo pathologic examination to rule out molar pregnancy.

Another frequent trap involves the post-evacuation surveillance period. Students forget that hCG must be monitored to undetectable and then continued monthly, and that pregnancy must be avoided during this window. A vignette may describe a patient whose hCG was falling and who then becomes pregnant, making it impossible to interpret whether a subsequent hCG rise represents recurrence or a new pregnancy. The tested concept: reliable contraception is not optional but a mandatory part of management.

Students also miss the association between complete mole and secondary hyperthyroidism. When a vignette pairs first-trimester bleeding with tachycardia, tremor, and weight loss, the test is checking whether you recognize hCG cross-reactivity with the TSH receptor rather than attributing these symptoms to anxiety or a separate thyroid disorder.

Finally, remember that suction curettage is always the answer for evacuation, not medical induction. And if hCG plateaus or rises after evacuation, the next step is staging and chemotherapy, not repeat curettage.